Immunic (NASDAQ:IMUX) Upgraded to “Strong-Buy” at Brookline Cap M

Immunic (NASDAQ:IMUX) was upgraded by stock analysts at Brookline Cap M to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for Immunic’s Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.46) EPS.

IMUX has been the subject of several other reports. HC Wainwright reduced their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Roth Mkm assumed coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. Brookline Capital Acquisition raised shares of Immunic to a “strong-buy” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Finally, Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Four equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $7.40.

Immunic Stock Performance

NASDAQ IMUX traded up $0.03 during trading on Tuesday, hitting $0.62. The stock had a trading volume of 1,185,491 shares, compared to its average volume of 1,481,856. Immunic has a 12 month low of $0.51 and a 12 month high of $1.39. The company’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.77. The company has a market capitalization of $74.58 million, a PE ratio of -0.75 and a beta of 1.58.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. As a group, equities analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its position in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after purchasing an additional 152,726 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after purchasing an additional 7,184,457 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic in the 3rd quarter valued at $81,000. Vanguard Group Inc. raised its holdings in shares of Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after buying an additional 219,957 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Immunic in the third quarter valued at about $170,000. 51.82% of the stock is currently owned by institutional investors.

Immunic News Summary

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Brookline Capital Management upgraded Immunic to a “Strong‑Buy” (reported by Zacks), a direct positive catalyst that can attract buyers and short‑covering. Zacks Upgrade
• Positive Sentiment: Brookline’s FY2026 outlook is materially less negative than the consensus — the firm forecasts FY2026 EPS of ($0.46) versus the street consensus of about ($0.94) — signaling an improving earnings trajectory that may be interpreted positively by investors. MarketBeat Report
• Neutral Sentiment: Brookline published detailed quarterly EPS forecasts (Q4 2025: -$0.12; Q1 2026: -$0.13; Q2 2026: -$0.12; Q3 2026: -$0.11; Q4 2026: -$0.10), providing investors with updated cadence for expected losses and potential milestones to watch. MarketBeat Forecasts
• Negative Sentiment: Despite the upgrade and smaller projected losses, Immunic remains unprofitable with consensus and Brookline forecasts still negative; the company’s small market cap, low share price and relatively thin liquidity increase execution and stock‑volatility risk for investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.